Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total value of $384,900.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $6,473,094.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Halozyme Therapeutics Trading Down 0.9 %
NASDAQ:HALO opened at $38.02 on Thursday. The company has a market capitalization of $4.83 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 0.46 and a beta of 1.25. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00. The stock has a fifty day simple moving average of $39.44 and a 200-day simple moving average of $37.76.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.33 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Research Report on HALO
Hedge Funds Weigh In On Halozyme Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Rise Advisors LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $25,000. Principal Securities Inc. acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $34,000. Advisory Services Network LLC raised its holdings in Halozyme Therapeutics by 50.5% in the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 303 shares during the last quarter. Belpointe Asset Management LLC raised its holdings in Halozyme Therapeutics by 42.0% in the 1st quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 366 shares during the last quarter. Finally, Harbour Investments Inc. acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $51,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Read More
- Five stocks we like better than Halozyme Therapeutics
- What is the NASDAQ Stock Exchange?
- United Airlines Soars on Earnings Beat
- Business Services Stocks Investing
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.